Amplia Therapeutics Ltd (ASX:ATX)'s Dr John Lambert speaks to Proactive about the company's March quarter, which saw the company receive an ethics green light to proceed with a phase two pancreatic cancer trial. The healthcare stock also initiated some key toxicology studies for its lead drug candidate, AMP945, which will open the door to other therapeutic areas beyond the cancer space. Dr Lambert says all the pieces are in place for the phase two AMP945 clinical trial, and the company is now preparing to recruit patients for the study.
Amplia Therapeutics gets trial green light, initiates toxicology studies in March quarter
